Likelihood of Approval and Phase Transition Success Rate Model – dasatinib

Pages: 3 Published: November 22, 2022 Report Code: GDDR457759LOA


How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models.

Likelihood of Approval (LoA) – Industry

dasatinib Drug Details

Dasatinib is under development for the treatment of chronic myeloid leukemia (CML) and acute lymphoblastic leukemia (ALL). It acts by targeting BCR-ABL. The drug candidate is developed based on HyNap technology. It is administered through oral route.

Report Coverage

The data is segmented by drug name and intervention type and shows the current likelihood of approval for the drug compared to both the indication benchmark and the industry benchmark so you can:

  • Get information on LOA and PTSR for competitors’ drugs to plan your clinical development, commercialization and marketing strategies
  • Track event-driven changes in LOA and PTSR benchmarked against indication LOA/PTSR
  • Use PTSR and LOA information and event-driven changes for your investment decisions to generate alpha

Additionally, this data is updated regularly based on events that take place which impact the clinical development process. GlobalData uses its proprietary machine learning models to track event-driven changes in LOA and PTSR and provides the quantitative changes to the likelihood of success along with the qualitative reasoning why the likelihood of approval has changed.

Quick View – LOA Data
Report Segments
· Drug type

· Intervention type

Drug Name
Administration Pathway
Therapeutic Areas
Key Manufacturers
Drug Development Status

Reasons to Buy

  • Allows clients to track and predict specific likelihood of approval and phase transition success rates of a drug using a combination of machine learning and proprietary models
  • Obtain information on LOA and PTSR for competitors’ drugs to plan your clinical development, commercialization and marketing strategies
  • Track event-driven changes in LOA and PTSR benchmarked against indication and industry values
  • Use PTSR and LOA information and event driven changes for your investment decisions to generate alpha

Key Players

Xspray Pharma AB

Frequently Asked Questions

The probability of a drug ultimately receiving market authorization

The probability of a drug’s advancement to the next stage of clinical development

GlobalData’s  Drug-Specific Likelihood of Approval (LoA) calculates the  Phase Transition Success Rate (PTSR) and  Likelihood of Approval (LoA) customized to individual drug. The model uses a combination of  Machine Learning (ML) and a  GlobalData proprietary algorithm to process data points from the  Drugs, Clinical Trials, Regulatory Milestones, Company, and  Financial databases.



Data Scope:

  • Drugs which have been approved in the past 10 years
  • Drugs which have failed during clinical development in the past 18 years
  • Drugs which are currently in development

Drug Phase Scope:

  • Phase I, Phase II, Phase III, and Pre-Registration development stage

Drug Geography Scope:

  • Drugs must meet one of the following criteria to be included in the model:
  • The developer has specified the US as an intended market for approval.
  • The developer has not specified any country as an intended market for approval, i.e. the “Drug Geography” is listed as “Global”

Drug Type Scope:

  • Innovator drugs and biosimilars

Entity Type Scope:

Only drugs in development by companies are included in the model.


  • Diagnostics, Imaging Agents, Biomarkers, stents and other drug delivery devices (covered in GlobalData’s Medical Intelligence Center).
  • Nutraceuticals, dietary supplements, alternative medicines, imaging agents, radio emitter, transplants, transfusions, fillers, cosmetics, probiotics, antiseptics, antacids, mobilizing agents, veterinary drugs and drugs not seeking approval.
  • Generic drugs
  • Innovative drugs in Preclinical or Discovery Stage.
  • Pipeline drugs sponsored by a Government or Institution.
  • Drugs with a specific Drug Geography not the United States.



Methodology – Machine Learning

  • GlobalData’s Drug-Specific Likelihood of Approval (LoA) models utilizes many attributes from Drugs, Clinical Trials, Review Designations and Company. The proprietary, machine learning algorithm is developed based on the impact of a specific attribute on PTSR and LoA.

Drug attributesTrial attributesCompany attributesRegulatory attributes

  • Development Stage
  • Therapy Area/ Indication
  • Target
  • Molecule Type
  • First-in-Class
  • Prior Approvals
  • Market Competitive Intensity
  • Drug Sales & Consensus Forecast

  • Trial Phase
  • Trial Status
  • Single country Vs. Multi country
  • Enrollment Efficiency
  • Biomarker
  • Interim Result
  • Trial Results

  • Market Capitalization
  • Development Partner Market Capitalization
  • Company with previous approvals
  • Licensing Agreements
  • Capital Raising
  • Partnership Strategy

  • Priority Review
  • Accelerated Approval
  • Fast Track Designation
  • Orphan Drug Designation
  • Breakthrough Therapy

  • The attributes with substantial impact on PTSR and LoA have the maximum weightage in the model, while the less impactful attributes have intermediate or low weightage.
  • PTSR and LoA scores are dynamic and are modified automatically with dynamic updates in drug, trials and company records. Time dependent variation is largely witnessed in the Clinical Trial attributes and influences the scores in positive or negative direction depending on its implication. This offers the user to examine the real time trajectory of clinical phase transition probability for a drug.

Methodology – Proprietary Model

  • GlobalData’s ML algorithm utilizes historical data to determine the probability of successful progression and market authorization for pipeline drugs from their current development stage. The historical data set is prepared to train the ML classifier. Once the algorithm is trained and recognizes a specific pattern, it is applied to the test data. The key learning are further tuned for hyperparameters to derive the optimum model.

ML Model Development

  • The ML model is further supplemented with an additional algorithm proprietary to GlobalData to predict PTSR and LoA. Each of the data attributes are assigned a weighted average score based on its direct impact on a drug’s clinical transition. The weighted average score represents a scale between a minimum to a maximum value based on the Raw Scores. The final score of an attribute is achieved by multiplying the Raw Score with the Weighted Score for each data attribute. All scores are added to determine the PTSR value.
  • LoA is calculated by compounding the PTSR at each stage the drug is yet to progress through. For example, to calculate the LoA for a drug in Phase I, the following formula is used: PTSR % Phase Ix PTSR % Phase II x PTSR % Phase III x PTSR % Pre-Registration.


Can be used by individual purchaser only


Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Get in touch to find out about our multi-purchase discounts
Tel +44 (0) 20 7947 2960

Every customer’s requirement is unique. We understand that and can customize the report basis your exact research requirements pertaining to market insights, innovation insights, strategy and planning, and competitive intelligence. You can also avail the option of purchasing stand-alone sections of the report or request for a country specific report.

Still undecided about purchasing this report?

Enquire Before Buying


“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods